Magnetic Resonance - Technology Information Portal Thursday, 29 July 2010••
Info
  Sheets


Out-
      side
 



 
 'GE Healthcare' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'GE Healthcare' found in 1 term [] and 22 definitions []
1 - 5 (of 23)     next
Result Pages : [1]  [2 3 4 5]
 bottom
MRI Resources  
Services and Supplies - Service and Support - Equipment - NMR - MR Myelography - Intraoperative MRI
 
GE HealthcareMRI Resource Directory:
 - Manufacturers -
 
www.gehealthcare.com GE Healthcare is the result of the merger between GE Medical and Amersham Health in Nov. 2004, after GE acquired Amersham Health for 9.5 billion in Oct. 2003. Jeffrey R. Immelt, Chairman of the Board and Chief Executive of General Electric, said, 'Amersham's diagnostic pharmaceutical and life sciences business will add new, high growth platforms to GE Medical's diagnostic imaging, services and healthcare information technology businesses'. GE Healthcare, a UK company, is a unit of General Electric (NYSE: GE). GE Healthcare is a global leader in medical imaging, diagnostic imaging contrast agents, interventional procedures, healthcare services, and information technology. For more than 100 years, health care providers have relied on GE Medical Systems, now GE Healthcare, for high quality medical technology and productivity solutions. GE Healthcare, headquartered now at formerly seat of Amersham Health in Great Britain, operates facilities around the world. Global Operations include organizations on the Americas, Europe, and Asia, including India, Japan, Korea China, Thailand and Vietnam.

MRI Related Product Lines:

Devices:
Signa HDx 3.0T
Signa HDx 1.5T
Signa HDe 1.5T
Signa 3.0T™
Signa Infinity 1.5T™ with Excite

Signa Infinity 1.5T™ TwinSpeed with Excite

Signa OpenSpeed™
Signa Ovation™
Signa Profile™

Older

SIGNA SP 0.5T™ Open Configuration
Signa Infinity 1.0T™

Contrast Agents:
Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Abdoscan® ?
Omniscan®
Teslascan®
Clariscan™


Contact Information
ONLINE www.gehealthcare.com
CONTACT INFO PAGE www.gehealthcare.com/contact
spacer
Further Reading:
  Basics:
GE Medical's new name: GE HealthcareOpen this link in a new window
Friday, 6 February 2004   by milwaukee.bizjournals.com    
  News & More:
MR Surgical Suite, Improving surgical procedure quality Open this link in a new window
Friday, 11 February 2005   by www.gehealthcare.com    
RSNA update on new MRI technology(.pdf)Open this link in a new window
February 2006   by www.magnet-mri.org    
MR Guided Focused Ultrasound, ExAblate 2000 - Non-invasive MR guided Focused Ultrasound Surgery for Uterine FibroidsOpen this link in a new window
Friday, 11 February 2005   by www.gehealthcare.com    
MRI's inside storyOpen this link in a new window
Thursday, 4 December 2003   by www.economist.com    
GE Healthcare, Insightec Sign Worldwide Sales and Marketing Agreement for ExAblate 2000 Focused Ultrasound System Non-Invasively Treats Uterine Fibroids; System Powered by GE Healthcare EquipmentOpen this link in a new window
Wednesday, 17 August 2005   by www.gehealthcare.com    
 •• There are 26 news about 'GE Healthcare'.
Omniscan®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Omniscan® is a nonionic chelate complex with low osmolality used as a paramagnetic MRI contrast agent. The efficacy of Omniscan® is similar to that of Gd-DTPA. Omniscan® is given intravenously to enhance images of intracranial and spinal lesions where there is abnormal vascularity or an abnormal blood brain barrier. The complex does not cross an intact blood brain barrier so Omniscan® only accumulates in lesions such as neoplasm's and abscesses.
See also Gadodiamide, and Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Gadodiamide, Gd-DTPA-BMA
DEVELOPER Winthrop Laboratories
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.9, r2=4.3, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 798 mosm/kgH2O
CONCENTRATION 287 mg/mL,0.5 mol/L
DOSAGE 0.1-0.2 mmol/kg / 0.2-0.4 ml/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 10 mL, 15 mL and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Omniscan® for sale GE Healthcare
EU Omniscan® for sale GE Healthcare
Australia Omniscan® for sale GE Healthcare

spacer
Further Reading:
  Basics:
Omniscan PharmacokineticsOpen this link in a new window
  News & More:
CONTRAST AGENTS IN MRI(.pdf)Open this link in a new window
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory ValueOpen this link in a new window
October 2004   by www.findarticles.com    
MRI Resources  
Fluorescence - Liver Imaging - Education pool - Jobs pool - RIS - Research Labs
 
GE LunarMRI Resource Directory:
 - Manufacturers -
 
www.gehealthcare.com [This entry is marked for removal.]

General Electric (GE) agreed to buy diagnostic systems maker Lunar Corp. for $150m. in March 2000. In 2004/05 it seems that the integration process into GE Healthcare has been completed. (GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

The U.S.-based company developed bone densitometers and scanning machines that measure bone density as a way of diagnosing osteoporosis and other metabolic bone diseases. GE Lunar marketed these products worldwide.
GE Lunar announced a distribution agreement with MagneVu for domestic sales of the MagneVu 1000, a portable MRI device for orthopedic use, under the trade name Applause™.
GE Lunar was the exclusive U.S. distributor of MR-devices manufactured by Esaote S.p.A. These compact in-office MRI™ machines are designed to fit all practice sizes in orthopedic imaging and complete the range of diagnostic imaging systems.
spacer
Further Reading:
  News & More:
Portable MR system aids diagnosis of rheumatic diseasesOpen this link in a new window
Sunday, 12 January 2003   by www.diagnosticimaging.com    
Signa HDe 1.5T™InfoSheet: - Devices -
Intro, 
Types of Magnets, 
Overview, 
etc.
 
From GE Healthcare;
www.vitalcom.com/euen/mri/products/signa-hde-15t/index.html GE Healthcare has added the Signa HDe 1.5T™, a compact MRI device at an affordable price to its family of MRI products. It has a single electronic cabinet that can be positioned inside the scanner room rather than in a separate equipment room. The Signa HDe 1.5T can be installed in the same physical location as 0.5T MRI systems with minimal construction costs. According to GE, the installation has been simplified to last only 7 days and has a 30 percent smaller footprint than a typical 1.5T system.
The 1.5T Signa® HDe MRI system is substantially equivalent to the currently marketed GE 1.5T machines. The data acquisition system supports 1, 4, 8 independent receive channels and multiple independent coil elements per channel during a single acquisition series. The gradient specifications of HDe are lower than other GE Signa 1.5T MRI systems, but it can support clinical applications in cardiac and spectroscopy imaging.

Device Information and Specification
CLINICAL APPLICATION Whole body
CONFIGURATION Compact short bore
SURFACE COILS Head and body coil standard; all other coils optional e.g., abdomen, spine, breast, knee, shoulder, cardiac imaging coils
SPECTROSCOPY Possible
SYNCHRONIZATION ECG/peripheral, respiratory gating, (SmartPrep, SmartStep)
PULSE SEQUENCES Standard: SE, IR, 2D/3D GRE and SPGR, Angiography: 2D/3D TOF, 2D/3D Phase Contrast; 2D/3D FSE, 2D/3D FGRE and FSPGR, SSFP, FLAIR, EPI
IMAGING MODES 2D single slice, multi slice, and 3D volume images, multi slab, cine
FOV 1 cm to 48 cm continuous
SLICE THICKNESS 2D 0.7 mm to 20 mm; 3D 0.1 mm to 5 mm
DISPLAY MATRIX 1028 x 1024
MEASURING MATRIX 128x512 steps 32 phase encode
PIXEL INTENSITY 256 gray levels
MAGNET TYPE Superconducting
POWER REQUIREMENTS 480 or 380/415
COOLING SYSTEM TYPE Closed-loop water-cooled gradient
CRYOGEN USE, L/hr less than 0.03 L/hr liquid helium
FIELD STRENGTH 1.5 T
spacer
Further Reading:
  Basics:
510(k) Summary 1.5T Signa® HDe MR System(.pdf)Open this link in a new window
Wednesday, 2 November 2005   by www.fda.gov    
Signa HDe 1.5TOpen this link in a new window
   by www.gehealthcare.com/    
 •• There is 1 news about 'Signa HDe 1.5T™'.
Teslascan®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.

Drug Information and Specification
NAME OF COMPOUND Mangafodipir trisodium, Manganese dipyroxyl diphosphate, MN-DPDP
DEVELOPER Amersham plc
CENTRAL MOIETY Mn2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=2.3, r2=4.0, B0=1.0 T
PHARMACOKINETIC Hepatobiliary, pancreatic, adrenal
OSMOLALITY 290 mosm/kgH2O
CONCENTRATION 0.01 mmol/L
DOSAGE 5 µmol/kg, 0.5 ml/kg
PREPARATION Finished product
INDICATION Liver lesions
DEVELOPMENT STAGE Approved
DISTRIBUTOR See below
PRESENTATION Vials of 100 ml
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Teslascan® for sale GE Healthcare
EU Teslascan® for sale GE Healthcare

spacer
Further Reading:
  Basics:
EMEA - Teslascan - SCIENTIFIC DISCUSSION(.pdf)Open this link in a new window
   by www.emea.europa.eu    
  News & More:
Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.Open this link in a new window
2002
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)Open this link in a new window
2002
CONTRAST AGENTS IN MRI(.pdf)Open this link in a new window
MRI Resources  
Abdominal Imaging - Cochlear Implant - Breast Implant - Hospitals - Non-English - Homepages
 
     1 - 5 (of 23)     next
Result Pages : [1]  [2 3 4 5]
 Random Page
 
MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Would like to get waked up on holidays by :
FLAIR 
spin echo 
gradient echo 
diffusion 
EPI 
NO! 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2010 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertising
 [last update: 2010-07-26 01:53:30]